Home › Atopic Dermatitis (Eczema) › NCT07782333
A Study Evaluating TRIV-573 in Atopic Dermatitis
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Has Atopic Dermatitis. * Has moderate to severe, active and symptomatic atopic dermatitis. Exclusion Criteria: * Severe or uncontrolled medical conditions. * Use of prohibited medications within stated washout periods.
About the study
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).
The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
What is being tested
- TRIV-573 (drug)
- Placebo (drug)
Sponsor: Triveni Bio · Participants: 90 · Started: Sep 9, 2026
Contact the study team
- Triveni Bio, Inc · Phone: +1 (781) 472-2230
Official record on ClinicalTrials.gov — NCT07782333
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.